Correlation between serum ischemia modified albumin and calmodulin expression levels and neurological impairment in patients with cerebral small vessel disease
Objective To investigate the correlation between serum ischemia modified albumin(IMA)and calmodulin(CaM)expression levels and neurological impairment in patients with cerebral small vessel disease.Methods The clinical data of 140 patients with cerebral small vessel disease(CSVD)who received treatment at The Third People Hospital in Liaocheng between April 2020 and December 2021 were retrospectively analyzed.On admission,serum levels of CaM and IMA were measured using an enzyme-linked immunosorbent assay and an albumin-cobalt binding test.Patients'neurological function was evaluated using the National Institutes of Health Stroke Scale(NIHSS).Patients'transient cerebral ischemia,urinary incontinence,and gait disturbance were evaluated using the National Institute of Neurological Disorders and Stroke Scale.Patients'cognitive function was evaluated using the Montreal Cognitive Assessment scale.The influential factors of serum IMA and CaM expression levels in patients with CSVD were analyzed.The factors that affect the severity of neuological imairment in patients with CSVD and their correlation with serum IMA and CaM expression levels were analyzed.Results The gender,age,presence or absence of gait disorders,and presence or absence of urinary incontinence of patients were not correlated with serum IMA and CaM levels(all P＞0.05).The serum levels of IMA[(38.5±5.3)× 103U/L,(38.5±4.7)×103U/L,(39.0±4.4)× 103U/L]and CaM[(190.4±34.5)μg/L,(191.2±26.7)μg/L,(199.7±24.8)μg/L]in patients with cognitive impairment,dizziness and vertigo,and transient cerebral ischemia were significantly higher than those in patients with normal cognitive function,patients without dizziness and vertigo,or patients without transient cerebral ischemia[(27.3±4.4)× 103U/L,(21.0±3.8)×103U/L,(20.5±5.1)×103U/L,(180.6±29.6)μg/L,(179.5±28.6)μg/L,(168.6±32.4)μg/L,t=14.10,24.36,22.50,all P＜0.05].There were significant differences in cognitive impairment(38/16/9),dizziness and vertigo(39/16/8),transient cerebral hemorrhage(35/16/9),NIHSS score[(3.6±0.8)points,(7.5±0.9)points,(16.2±3.2)points],CaM levels[(125.3± 20.5)μg/L,(185.5±23.6)μg/L,(237.9±54.3)μg/L],and IMA levels[(21.2±3.5)]×103 U/L,[(38.5± 4.3)×103 U/L,(74.9±5.4)×103 U/L]among patients with mild,moderate,and severe neurological impairment(t=32.87,11.28,12.42,34.59,151.73,147.84,all P＜0.05).The results of multivariate analysis indicated that cognitive impairment(OR=1.578,95％CI:1.043-2.386),transient cerebral ischemia(OR=2.396,95％CI:1.156-4.969),dizziness and vertigo(OR=1.906,95％CI:1.086-3.345),NIHSS score(OR=2.171,95％CI:1.162-4.056),CaM level(OR=2.022,95％CI:1.268-3.224),and increased IMA levels(OR=2.090,95％CI:1.313-3.325)were independent influential factors for worsened neurological impairment(all P＜0.05).The serum levels of IMA and CaM in patients with CSVD were significantly positively correlated with the severity of neurological impairment(r=5.45,8.33,both P＜0.05).Conclusion The elevated serum levels of IMA and CaM in patients with CSVD serve as independent risk factors for neurological impairment,and these levels are positively correlated with the severity of neurological impairment.
Cerebral small vessel diseasesReceptor activity-modifying proteinsCalmodulinCognitive dysfunctionDizzinessIschemic attack,transientRisk factors
NETL
NSTL
维普
万方数据
